Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling

Expert Review of Respiratory Medicine

Volumn 5, Issue 5, 2011, Pages 623-625

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

airway remodeling; asthma; LIGHT; TNF superfamily members; TNF

Indexed keywords

ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 13; LYMPHOTOXIN BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIGHT; UNCLASSIFIED DRUG;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHMA; EOSINOPHILIA; HYPERPLASIA; INFLAMMATORY CELL; LUNG FIBROSIS; MOUSE; NONHUMAN; REVIEW; SMOOTH MUSCLE;

EID: 80053365600     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.65     Document Type: Review

References (19)

1. Matera ML, Calzetta L, Cazzola M. TNF-a inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm. Pharmacol. Ther. 23, 121-128 (2010).
2. Doherty TA, Soroosh P, Khorram N et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat. Med. 17, 596-603 (2011).
3. Kips JC, Tavernier JH, Joos GF et al. The potential role of tumour necrosis factor a in asthma. Clin. Exp. Allergy 23, 247-250 (1993). (Pubitemid 23142763)
4. Brightling C, Berry M, Amrani Y. Targeting TNF-a: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121, 5-10 (2008).
5. Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor a blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549-558 (2009).
6. Aoki T, Hirota T, Tamari M et al. An association between asthma and TNF-308G/A/polymorphism: meta analysis. J. Hum. Genet. 51, 677-685 (2006). (Pubitemid 44354679)
7. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 368, 804-813 (2006). (Pubitemid 44279058)
8. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov. Today 14, 1082-1088 (2009).
9. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271-285 (2009).
10. Ware CF. Targeting the LIGHT-HVEM pathway. Adv. Exp. Med. Biol. 647, 146-155 (2009).
11. Ware CF. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol. Rev. 223, 186-201 (2008). (Pubitemid 351986174)
12. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin a are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998). (Pubitemid 28097820)
13. Bai C, Connolly B, Metzker ML et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl Acad. Sci. USA 97, 1230-1235 (2000). (Pubitemid 30080841)
14. Seshasayee D, Lee WP, Zhou M et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 117, 3868-3878 (2007). (Pubitemid 350224096)
15. Durham A, Adcock IM, Tliba O. Steroid resistance in severe asthma: current mechanisms and future treatment. Curr. Pharm. Des. 17, 674-684 (2011).
16. Gupta S, Siddiqui S, Haldar P et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 65, 775-781 (2010).
17. Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol. Rev. 223, 202-220 (2008). (Pubitemid 351986178)
18. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 19, 676-680 (2007) (Pubitemid 350236803)
19. Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling? Current perspectives. J. Allergy Clin. Immunol. 128(3), 439-448 (2011